ArticleScientific reports2025
Trends in net survival from cervical cancer in a Brazilian state with medium Human Development Index.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cervical cancer remains a major public health concern in Northeast Brazil, ranking as the second most common cancer among women. This study provides the first long-term, population-based estimates of net survival from cervical cancer in Sergipe, a Brazilian state with a medium Human Development Index, using high-quality registry data subjected to rigorous quality control procedures. We analysed data for 3,977 women aged 15-99 years diagnosed with an invasive cervical cancer between 1996 and 2017 and followed up to 2022, after excluding 6,095 in situ neoplasms. Net survival was estimated using the Pohar Perme method, stratified by histological subtype and calendar period, and age-standardised with the International Cancer Survival Standard weights. We observed a substantial decline in survival over time: one-year net survival dropped from 84.6% (1996-1999) to 73.4% (2015-2017), and five-year survival from 60.8 to 49.3%. Squamous cell carcinoma and adenocarcinoma showed similar survival patterns, with five-year survival ranging from 55 to 58%. The persistent decline in net survival may reflect a shift toward more advanced or aggressive invasive cancers, as screening programmes increasingly detect and remove early-stage lesions. Delayed diagnosis and sub-optimal treatment further contribute, underscoring the need to improve screening and timely cancer care access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.